LTS-101
CLN2 Disease – CNS
About Latus Bio
Latus Bio is a private, pre-clinical stage biotech leveraging high-throughput screening and computational methods to discover novel AAV capsids for targeted gene therapy. The company's platform aims to enable tissue-specific delivery, dramatically lower therapeutic doses, reduce toxicity, and decrease manufacturing costs. Its initial pipeline targets severe monogenic CNS disorders, including Huntington's disease and CLN2 Batten disease, with programs advancing toward clinical development.
View full company profileAbout Latus Bio
Latus Bio is a private, pre-clinical stage biotech leveraging high-throughput screening and computational methods to discover novel AAV capsids for targeted gene therapy. The company's platform aims to enable tissue-specific delivery, dramatically lower therapeutic doses, reduce toxicity, and decrease manufacturing costs. Its initial pipeline targets severe monogenic CNS disorders, including Huntington's disease and CLN2 Batten disease, with programs advancing toward clinical development.
View full company profile